Our Science

EPICC Platform And Our Unique Dual Targeting Mechanisms Of Action

The EPICC platform presents a novel opportunity to modify disease progression through moderation of the most robust components of both humoral (complement system) and cellular (neutrophils) components of innate inflammatory responses.

First Target

Complement Pathway

EPICC molecules rapidly and dose dependently inhibit C1 and MBL, the earliest initiators of the classical and lectin complement pathway. Inhibition is via transformational changes of serine proteases at C1 and MBL.

Learn More
Second Target

Inhibiting Innate Inflammatory Processes

In addition to complement modulation, the EPICC platform acts as a potent inhibitor of innate, neutrophil-mediated, inflammatory processes.

Learn More
Our Clinical Pipeline

ReAlta Life Sciences' Research And Development
Initiatives Focus On Acute Inflammatory and Rare Diseases

Hypoxic Ischemic Encephalopathy

Hypoxic-ischemic encephalopathy (HIE) is a type of newborn brain damage caused by oxygen deprivation and limited blood flow.

Learn More
Acute Exacerbations of COPD

Acute Exacerbations of COPD (AE COPD) affect individuals suffering from COPD, leading to worsening lung function and hospitalization. This inflammatory disease is primarily driven by neutrophils recruited into the lungs.

Learn More
Graft-versus-Host Disease

Graft-versus-Host Disease (GvHD) is a common disease following bone marrow transplantation where the transplanted white blood cells begin to attack the host body including skin, liver and intestines.

Learn More
Platelet Refractoriness

Platelet Refractoriness is common in cancer patients who receive frequent platelet transfusions and increases the risk of life-threatening hemorrhage.

Learn More

Number of peer-reviewed publications and index studies on RLS-0071


Patents and patent applications active in: US, Europe (including many EU countries), Australia, Canada, Japan, China, UAE, South Korea, Mexico, Singapore, Saudi Arabia, Israel, Kuwait, India, South Africa.


Number of engineered peptides with potential for treating conditions in many therapeutic areas through its unique dual targeting mechanism.

Dscf2958 Mirror
ReAlta Life Sciences
Core Values
  • Do What Is Right For The Patient
  • Integrity
  • Go Beyond
  • Foster Creative Tension
  • All for One, One for All

Latest News & Events